Helen Boucher
#25,770
Most Influential Person Now
American physician
Helen Boucher's AcademicInfluence.com Rankings
Helen Boucherphilosophy Degrees
Philosophy
#11378
World Rank
#15664
Historical Rank
Logic
#8196
World Rank
#10214
Historical Rank
Download Badge
Philosophy
Helen Boucher's Degrees
- Doctorate Medicine Harvard University
Why Is Helen Boucher Influential?
(Suggest an Edit or Addition)According to Wikipedia, Helen Boucher is Dean of Tufts University School of Medicine and Chief Academic Officer of Tufts Medicine, the parent health system for Tufts Medical Center in Boston. Prior to this, she served as Chief of the Division of Geographic Medicine and Infectious Diseases at Tufts Medical Center, a Professor of Medicine at Tufts University School of Medicine, and Director of the Stuart B. Levy Center for Integrated Management of Antimicrobial Resistance at Tufts.
Helen Boucher's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. (2009) (3704)
- The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. (2008) (1496)
- Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. (2006) (1131)
- Epidemiology of methicillin-resistant Staphylococcus aureus. (2008) (888)
- Combating antimicrobial resistance: policy recommendations to save lives. (2011) (655)
- 10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. (2013) (589)
- The 10 x '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. (2010) (355)
- Once-weekly dalbavancin versus daily conventional therapy for skin infection. (2014) (351)
- Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial. (2013) (308)
- Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. (2009) (293)
- Serious infections caused by methicillin-resistant Staphylococcus aureus. (2010) (263)
- RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections (2019) (222)
- Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications (2017) (207)
- Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. (2007) (165)
- Newer systemic antifungal agents : pharmacokinetics, safety and efficacy. (2004) (152)
- Current concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococci. (2011) (134)
- Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates (2008) (123)
- In Vitro Activities of the Glycylcycline GAR-936 against Gram-Positive Bacteria (2000) (103)
- The Infectious Diseases Society of America's 10 × '20 Initiative (10 New Systemic Antibacterial Agents US Food and Drug Administration Approved by 2020): Is 20 × '20 a Possibility? (2019) (98)
- White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens. (2012) (98)
- Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients. (2008) (97)
- Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. (2005) (96)
- Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: update from the Biomarkers Consortium of the Foundation for the National Institutes of Health. (2012) (86)
- A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study) (2020) (83)
- White Paper: Developing Antimicrobial Drugs for Resistant Pathogens, Narrow-Spectrum Indications, and Unmet Needs (2017) (82)
- Associations between the Genotypes of Staphylococcus aureus Bloodstream Isolates and Clinical Characteristics and Outcomes of Bacteremic Patients (2008) (79)
- Screening of donor and candidate prior to solid organ transplantation—Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice (2019) (74)
- Antimicrobial agents for complicated skin and skin-structure infections: justification of noninferiority margins in the absence of placebo-controlled trials. (2009) (70)
- Newer Systemic Antifungal Agents (2012) (66)
- Outcomes with daptomycin versus standard therapy for osteoarticular infections associated with Staphylococcus aureus bacteraemia. (2008) (63)
- Challenges in anti-infective development in the era of bad bugs, no drugs: a regulatory perspective using the example of bloodstream infection as an indication. (2010) (60)
- Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies (2015) (54)
- Community-based outpatient parenteral antimicrobial therapy (CoPAT) for Staphylococcus aureus bacteraemia with or without infective endocarditis: analysis of the randomized trial comparing daptomycin with standard therapy (2009) (52)
- Clinical implications of stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: a study of 69 patients at 2 university hospitals. (2000) (50)
- Position paper: recommended design features of future clinical trials of antibacterial agents for community-acquired pneumonia. (2008) (48)
- Emergency Use Authorization of Remdesivir: The Need for a Transparent Distribution Process. (2020) (47)
- Effect of Algorithm-Based Therapy vs Usual Care on Clinical Success and Serious Adverse Events in Patients with Staphylococcal Bacteremia: A Randomized Clinical Trial (2018) (40)
- Clinical characteristics and outcomes of diabetic patients with Staphylococcus aureus bacteremia and endocarditis (2009) (38)
- Gram-Positive Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group. (2017) (36)
- Dalbavancin for the treatment of acute bacterial skin and skin structure infections (2015) (35)
- New agents for Staphylococcus aureus endocarditis (2006) (34)
- Chloramphenicol treatment for vancomycin-resistant Enterococcus faecium bacteremia. (2001) (34)
- Antibiotic resistance in the patient with cancer: Escalating challenges and paths forward (2021) (32)
- Gram-negative bloodstream infections. (2009) (31)
- Considerations for Clinical Trials of Staphylococcus aureus Bloodstream Infection in Adults (2018) (29)
- Good Studies Evaluate the Disease While Great Studies Evaluate the Patient: Development and Application of a Desirability of Outcome Ranking Endpoint for Staphylococcus aureus Bloodstream Infection. (2018) (28)
- Drug-Use and Post-Operative Mortality Following Valve Surgery for Infective Endocarditis: A Systematic Review and Meta-Analysis. (2019) (27)
- Cost Advantage of Voriconazole over Amphotericin B Deoxycholate for Primary Treatment of Invasive Aspergillosis (2005) (26)
- Daptomycin compared to standard therapy for the treatment of native valve endocarditis. (2010) (25)
- The United Nations and the Urgent Need for Coordinated Global Action in the Fight Against Antimicrobial Resistance (2016) (23)
- To treat or not to treat: adjunctive antibiotics for uncomplicated abscesses. (2011) (21)
- Targeting antimicrobial-resistant bacterial respiratory tract pathogens: it is time to ‘get smart’ (2015) (21)
- BAD BUGS, NO DRUGS 2002-2020: PROGRESS, CHALLENGES, AND CALL TO ACTION. (2020) (21)
- First report of a left ventricular assist device infection caused by Staphylococcus schleiferi subspecies coagulans: a coagulase-positive organism. (2012) (17)
- Partial Oral Therapy for Osteomyelitis and Endocarditis - Is It Time? (2019) (14)
- Infections in immunocompromised patients. (2009) (14)
- Evaluation of Renal Safety Between Imipenem/Relebactam and Colistin Plus Imipenem in Patients With Imipenem-Nonsusceptible Bacterial Infections in the Randomized, Phase 3 RESTORE-IMI 1 Study (2020) (14)
- BK Virus Nephropathy in Heart Transplant Recipients. (2015) (14)
- Comparison of Treatment Outcomes between Analysis Populations in the RESTORE-IMI 1 Phase 3 Trial of Imipenem-Cilastatin-Relebactam versus Colistin plus Imipenem-Cilastatin in Patients with Imipenem-Nonsusceptible Bacterial Infections (2020) (13)
- Design of clinical trials of antibacterial agents for community-acquired bacterial pneumonia. (2011) (12)
- In Vivo Activity of Evernimicin (SCH 27899) against Methicillin-Resistant Staphylococcus aureus in Experimental Infective Endocarditis (2001) (12)
- Weekly SARS-CoV-2 screening of asymptomatic kindergarten to grade 12 students and staff helps inform strategies for safer in-person learning (2021) (11)
- Molecular epidemiology of Staphylococcus aureus in post-earthquake northern Haiti. (2014) (10)
- Early high-dose daptomycin for methicillin-resistant Staphylococcus aureus bloodstream infections with elevated vancomycin minimum inhibitory concentrations: ready for prime time? (2013) (9)
- Daptomycin for methicillin-resistant Staphylococcus aureus bloodstream infection and elevated vancomycin minimum inhibitory concentrations: has the time come? (2012) (9)
- LB-1. Efficacy and Safety of Oral Sulopenem Etzadroxil/Probenecid Versus Oral Ciprofloxacin in the Treatment of Uncomplicated Urinary Tract Infections (uUTI) in Adult Women: Results from the SURE-1 Trial (2020) (8)
- Trichodysplasia spinulosa: Case reports and review of literature (2020) (7)
- Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt. (2006) (6)
- Is it possible to blind a trial for community-acquired pneumonia? (2008) (6)
- Editorial commentary: imminent challenges: carbapenem-resistant enterobacteriaceae in transplant recipients and patients with hematologic malignancy. (2014) (6)
- U.S. Efforts to Curb Antibiotic Resistance - Are We Saving Lives? (2020) (6)
- MICROBIOLOGIC ANALYSES OF TARGET PATHOGENS IDENTIFIED IN THE DALBAVANCIN DISCOVER PROGRAM (2013) (5)
- Proposed U.S. Funding Cuts Threaten Progress on Antimicrobial Resistance (2017) (5)
- Antibacterial Resistance Leadership Group 2.0 - Back to Business. (2021) (5)
- A Desirability of Outcome Ranking Analysis of a Randomized Clinical Trial Comparing Seven Versus Fourteen Days of Antibiotics for Uncomplicated Gram-Negative Bloodstream Infection (2022) (4)
- Antibiotics for skin infections: new study design and a step toward shorter course therapy. (2013) (4)
- Bacterial antibiotic resistance development and mutagenesis following exposure to subinhibitory concentrations of fluoroquinolones in vitro: a systematic review of the literature (2020) (4)
- What’s Hot in Clinical Infectious Diseases? 2019 IDWeek Summary (2020) (4)
- Disseminated mucormycosis masquerading as rejection early after orthotopic heart transplantation (2018) (4)
- 1339. Results for the Supplemental Microbiological Modified Intent-to-Treat (SmMITT) Population of the RESTORE-IMI 1 Trial of Imipenem/Cilastatin/Relebactam (IMI/REL) vs. Imipenem/Cilastatin Plus Colistin (IMI+CST) in Patients with Imipenem-Nonsusceptible (NS) Bacterial Infections (2018) (3)
- 266Dalbavancin vs Vancomycin for the treatment of acute bacterial skin and skin structure infections (ABSSSI): a subanalysis from the DISCOVER studies (2014) (3)
- Antibiotic Development Incentives That Reflect Societal Value of Antibiotics. (2020) (3)
- The Fight Against Multidrug-Resistant Bacteria (2017) (3)
- Sulopenem or Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Women: A Phase 3, Randomized Trial (2022) (3)
- Outcomes with Daptomycin vs. Standard Therapy for S. aureus Bone and Joint Infections (2006) (2)
- 1444. Characterization of a Novel Pathogen in Immunocompromised Patients: Elizabethkingia Anopheles (2020) (2)
- Dalbavancin or oritavancin for skin infections. (2014) (2)
- Reply to Paul and Leibovici. (2018) (1)
- BAC DOOR: A Clinician Ranking Exercise for Better Staphylococcus aureus Bacteremia Trial Design (2016) (1)
- Combination Therapy with Daptomycin (2008) (1)
- Factors associated with neutropenia post heart transplantation (2021) (1)
- Rifampin-containing regimens for community-associated skin infection: a hazard without known benefit. (2009) (1)
- Reply to Tillotson, Outterson et al, and Burgess et al (2010) (1)
- Deploying the Physician Workforce During a Respiratory Pandemic: The Experience of an Academic Teaching Hospital During the COVID-19 Pandemic (2021) (1)
- 1951. Nephrotoxicity Associated With Imipenem/Cilastatin/Relebactam (IMI/REL) vs. Imipenem/Cilastatin Plus Colistin (IMI+CST) in Patients With Imipenem-Nonsusceptible (NS) Bacterial Infections (2018) (1)
- Reply to Kunin: Rationale for Antibiotic Development Incentives (2008) (1)
- Reply to Bruss (2009) (0)
- Doing the Same with Less: A Randomized, Multinational, Open-Label, Adjudicator-Blinded Trial of an Algorithm vs. Standard of Care to Determine Treatment Duration for Staphylococcal Bacteremia (2017) (0)
- An Unusual Case of Cellulitis (2018) (0)
- The Role of Ceftazidome Avibactam for MDR Gram-Negative Bacteria (2018) (0)
- What' New (2012) (0)
- Characterization of a Novel Pathogen in Immunocompromised Patients: Elizabethkingia anophelis-Exploring the Scope of Resistance to Contemporary Antimicrobial Agents and β-lactamase Inhibitors. (2023) (0)
- Confirmed Faculty Listing for Tufts CSDD's 2014 Annual Postgraduate Course in Clinical Pharmacology Drug Development, and Regulation (2014) (0)
- 652. Ceftazidime-avibactam Alone or as Combination Therapy? Multicenter Retrospective Cohort Analysis of Clinical Outcomes in Patients with Carbapenem-resistant Gram-negative Infection (2022) (0)
- Reply to DiNubile. (2015) (0)
- Gram-Positive Antibacterials (2016) (0)
- Common Drug Interactions Encountered in Treating Transplant-Related Infection (2016) (0)
- Dr. Cosgrove and colleagues reply [4] (2006) (0)
- Drugs 2004; 64 (18): 1997-2020 (2004) (0)
- 223. Development and Analysis of a Novel DOOR Endpoint for Complicated Intra-abdominal Infections (cIAI) Using 10 Registrational Trials for Antibacterial Drugs (2022) (0)
- Length of Therapy and Outcome in S. aureus bacteremia and Endocarditis (SAB/SAIE): < 14 Days of Therapy Associated with Lower Success Rates in Uncomplicated SAB (uB) (2006) (0)
- Antibacterials: Gram-Positives (2015) (0)
- Editorial commentary: the Department of Defense fights the battle against antimicrobial resistance: can the United States win the war? (2014) (0)
- MRSA Edited by John A. Weigelt New York: Informa Healthcare, 2007. 232 pp. $99.95 (softcover). (2008) (0)
- Faculty List for Tufts CSDD 2016 Annual Postgraduate Course in Clinical Pharmacology Drug Development, and Regulation (2016) (0)
- Improving Traditional Registrational Trial Endpoints: Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Complicated Urinary Tract Infection Clinical Trials. (2022) (0)
- How Bacteremia Strategy Trials Will Impact the Clinical Practice of Infectious Diseases (2018) (0)
- 675Outcomes of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) by vancomycin dosing regimen and vancomycin trough serum concentrations in the DISCOVER Program (2014) (0)
- A tribute to Dr Robert C. Moellering Jr (1937-2014). (2014) (0)
- P850 Comparison of clinical outcomes in patients with Staphylococcus aureus bacteraemia and endocarditis presenting with or without systemic infiammatory response syndrome (2007) (0)
- Applying DOOR endpoints. (2023) (0)
- Drugs for S. aureus : 2009 (2009) (0)
- IDSA Society Citation (2015) (0)
- Antimicrobial and Diagnostic Stewardship (2018) (0)
- Analysis of CAMERA-1 S. aureus Bacteremia Trial Results using the DOOR (2017) (0)
- Clinical Trials that May Change Your Practice (2018) (0)
- Coronavirus disease 2019 (COVID-19) vaccinations and preservation of the healthcare workforce (2021) (0)
- CONSULTING EDITOR EDITORS (2018) (0)
- Kidney Biopsy Teaching Case BK Virus Nephropathy in Heart Transplant Recipients (2015) (0)
- Exploration of a Potential DOOR Endpoint for Complicated Intra-Abdominal Infections Using Nine Registrational Trials for Antibacterial Drugs. (2023) (0)
- Advances in Management of Bacteremia and Sepsis (2017) (0)
This paper list is powered by the following services:
Other Resources About Helen Boucher
What Schools Are Affiliated With Helen Boucher?
Helen Boucher is affiliated with the following schools:
